Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.
Hirsch
L J
LJ
Comprehensive Epilepsy Center, Department of Neurology, Mailman School of Public Health, Columbia University, 710 W. 168 St., Box NI-135, New York, NY 10032, USA. ljh3@columbia.edu
Weintraub
D
D
Du
Y
Y
Buchsbaum
R
R
Spencer
H T
HT
Hager
M
M
Straka
T
T
Bazil
C W
CW
Adams
D J
DJ
Resor
S R
SR
Morrell
M J
MJ
D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D012189:Retrospective Studies; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use
D000927:Anticonvulsants; D014227:Triazines; D014635:Valproic Acid; D000077213:Lamotrigine